Abraxane Gets Approval For Metastatic Breast Cancer Treatment In Quebec

Abraxis has received a recommendation from the Quebec Conseil du Medicament and approval from the Quebec Ministry of Health for Abraxane, for Injectable Suspension 100mg in Quebec. It is intended for the treatment of metastatic breast cancer.

Approval was based upon comparative clinical trials, demonstrating that the tumor response rate of Abraxane was nearly double for patients who received Abraxane, as compared to those who received solvent-based paclitaxel. Patients treated with Abraxane experienced a significant improvement in progression-free survival and prolonged time to tumor progression, compared to patients treated with solvent-based paclitaxel.i

Abraxane has now been approved in 36 countries across Europe, North America, Asia and Australia. Abraxis is continuing to expand its clinical experience with Abraxane and its potential in treating tumor types at multiple stages of disease, as a single agent and in combination.

Andre Robidoux, Director of the Breast Cancer Research Group, CHUM Research Center, said: Based on clinical study results to date and my first-hand experience, I believe that Abraxane represents a very important and needed new treatment option for breast cancer. Abraxane is the only taxane that is solvent free and is approved to treat metastatic breast cancer.”